FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004809264> ?p ?o ?g. }

• W2004809264 endingPage "1699" @default.
• W2004809264 startingPage "1691" @default.
• W2004809264 abstract "The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy.BackgroundDiabetic nephropathy is characterized by glomerular hypertrophy. We have recently shown that experimental diabetes mellitus is associated with an increase in glomerular expression of the cyclin kinase inhibitor p21WAF1/CIP1 (p21). Furthermore, in vitro glucose-induced mesangial cell hypertrophy is also associated with an up-regulated expression of p21. In this study, we tested the hypothesis that p21 mediates diabetic glomerular hypertrophy in vivo.MethodsExperimental diabetes mellitus was induced by streptozotocin in mice in which p21 was genetically deleted (p21 -/-) and in wild-type mice (p21 +/+). Kidney biopsies were obtained from diabetic and control (citrate injected) p21 +/+ and p21 -/- mice at day 60. The tissue was used for morphologic studies of glomerular size (measured by computer image-analysis system), glomerular cellularity (cell count), glomerular matrix expansion (silver stain), apoptosis (TUNEL), and expression of transforming growth factor-βbgr;1 (TGF-βbgr;1) by in situ hybridization.ResultsThe glomerular tuft area increased 11.21% in diabetic p21 +/+ mice at day 60 compared with control (3329.98 ± 244.05 μm2 vs. 2994.39 ± 176.22 μm2, P = 0.03), and the glomerular cell count did not change in diabetic p21 +/+ mice at day 60 compared with the control. These findings are consistent with glomerular hypertrophy. In contrast, the glomerular tuft area did not increase in diabetic p21 -/- mice at day 60 compared with the control (3544.15 ± 826.49 vs. 3449.15 ± 109.65, P = 0.82), nor was there an increase in glomerular cell count (41.41 ± 13.18 vs. 46.95 ± 3.00, P = 0.43). Diabetic p21 +/+ mice, but not p21 -/- mice, developed an increase in proteinuria at day 60 compared with the control. Tubular cell proliferation, measured by proliferating cell nuclear antigen immunostaining, was increased in both diabetic p21 +/+ (2.1-fold) and p21 -/- (7.61-fold) mice compared with controls. Glomerular cell apoptosis did not increase in diabetic mice. Although glomerular TGF-βbgr;1 mRNA levels increased in both strains of diabetic mice at day 60, the glomerular matrix did not expand.ConclusionsHyperglycemia was associated with glomerular hypertrophy in p21 +/+ mice. Despite the increase in TGF-βbgr;1 mRNA, diabetic p21 -/- mice did not develop glomerular hypertrophy, providing evidence that the cyclin kinase inhibitor p21 may be required for diabetic glomerular hypertrophy induced by TGF-βbgr;1. The loss of p21 increases tubular but not glomerular cell proliferation in diabetic nephropathy. The absence of glomerular hypertrophy appears protective of renal function in diabetic mice. The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Diabetic nephropathy is characterized by glomerular hypertrophy. We have recently shown that experimental diabetes mellitus is associated with an increase in glomerular expression of the cyclin kinase inhibitor p21WAF1/CIP1 (p21). Furthermore, in vitro glucose-induced mesangial cell hypertrophy is also associated with an up-regulated expression of p21. In this study, we tested the hypothesis that p21 mediates diabetic glomerular hypertrophy in vivo. Experimental diabetes mellitus was induced by streptozotocin in mice in which p21 was genetically deleted (p21 -/-) and in wild-type mice (p21 +/+). Kidney biopsies were obtained from diabetic and control (citrate injected) p21 +/+ and p21 -/- mice at day 60. The tissue was used for morphologic studies of glomerular size (measured by computer image-analysis system), glomerular cellularity (cell count), glomerular matrix expansion (silver stain), apoptosis (TUNEL), and expression of transforming growth factor-βbgr;1 (TGF-βbgr;1) by in situ hybridization. The glomerular tuft area increased 11.21% in diabetic p21 +/+ mice at day 60 compared with control (3329.98 ± 244.05 μm2 vs. 2994.39 ± 176.22 μm2, P = 0.03), and the glomerular cell count did not change in diabetic p21 +/+ mice at day 60 compared with the control. These findings are consistent with glomerular hypertrophy. In contrast, the glomerular tuft area did not increase in diabetic p21 -/- mice at day 60 compared with the control (3544.15 ± 826.49 vs. 3449.15 ± 109.65, P = 0.82), nor was there an increase in glomerular cell count (41.41 ± 13.18 vs. 46.95 ± 3.00, P = 0.43). Diabetic p21 +/+ mice, but not p21 -/- mice, developed an increase in proteinuria at day 60 compared with the control. Tubular cell proliferation, measured by proliferating cell nuclear antigen immunostaining, was increased in both diabetic p21 +/+ (2.1-fold) and p21 -/- (7.61-fold) mice compared with controls. Glomerular cell apoptosis did not increase in diabetic mice. Although glomerular TGF-βbgr;1 mRNA levels increased in both strains of diabetic mice at day 60, the glomerular matrix did not expand. Hyperglycemia was associated with glomerular hypertrophy in p21 +/+ mice. Despite the increase in TGF-βbgr;1 mRNA, diabetic p21 -/- mice did not develop glomerular hypertrophy, providing evidence that the cyclin kinase inhibitor p21 may be required for diabetic glomerular hypertrophy induced by TGF-βbgr;1. The loss of p21 increases tubular but not glomerular cell proliferation in diabetic nephropathy. The absence of glomerular hypertrophy appears protective of renal function in diabetic mice." @default.
• W2004809264 created "2016-06-24" @default.
• W2004809264 creator A5018785830 @default.
• W2004809264 creator A5022177889 @default.
• W2004809264 creator A5034911775 @default.
• W2004809264 creator A5046541559 @default.
• W2004809264 creator A5047698585 @default.
• W2004809264 creator A5058823472 @default.
• W2004809264 date "1999-11-01" @default.
• W2004809264 modified "2023-10-10" @default.
• W2004809264 title "The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy" @default.
• W2004809264 cites W1608791497 @default.
• W2004809264 cites W1973047647 @default.
• W2004809264 cites W1974391793 @default.
• W2004809264 cites W1975324295 @default.
• W2004809264 cites W1976577674 @default.
• W2004809264 cites W1977212183 @default.
• W2004809264 cites W1978669288 @default.
• W2004809264 cites W1978747049 @default.
• W2004809264 cites W1986639245 @default.
• W2004809264 cites W1990743609 @default.
• W2004809264 cites W1994887713 @default.
• W2004809264 cites W2000519471 @default.
• W2004809264 cites W2003907692 @default.
• W2004809264 cites W2009775031 @default.
• W2004809264 cites W2014501553 @default.
• W2004809264 cites W2015066175 @default.
• W2004809264 cites W2017740165 @default.
• W2004809264 cites W2019316722 @default.
• W2004809264 cites W2053295407 @default.
• W2004809264 cites W2054842941 @default.
• W2004809264 cites W2056420854 @default.
• W2004809264 cites W2057655548 @default.
• W2004809264 cites W2061202476 @default.
• W2004809264 cites W2066848701 @default.
• W2004809264 cites W2072670533 @default.
• W2004809264 cites W2081451346 @default.
• W2004809264 cites W2089218510 @default.
• W2004809264 cites W2091321868 @default.
• W2004809264 cites W2091754751 @default.
• W2004809264 cites W2092433658 @default.
• W2004809264 cites W2094446617 @default.
• W2004809264 cites W2094697218 @default.
• W2004809264 cites W2128230258 @default.
• W2004809264 cites W2138852914 @default.
• W2004809264 cites W2140437192 @default.
• W2004809264 cites W2155009865 @default.
• W2004809264 cites W2155278362 @default.
• W2004809264 cites W2173187023 @default.
• W2004809264 cites W2260058514 @default.
• W2004809264 cites W4234678377 @default.
• W2004809264 doi "https://doi.org/10.1046/j.1523-1755.1999.00728.x" @default.
• W2004809264 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10571777" @default.
• W2004809264 hasPublicationYear "1999" @default.
• W2004809264 type Work @default.
• W2004809264 sameAs 2004809264 @default.
• W2004809264 citedByCount "108" @default.
• W2004809264 countsByYear W20048092642012 @default.
• W2004809264 countsByYear W20048092642013 @default.
• W2004809264 countsByYear W20048092642014 @default.
• W2004809264 countsByYear W20048092642016 @default.
• W2004809264 countsByYear W20048092642017 @default.
• W2004809264 countsByYear W20048092642019 @default.
• W2004809264 countsByYear W20048092642020 @default.
• W2004809264 countsByYear W20048092642021 @default.
• W2004809264 countsByYear W20048092642022 @default.
• W2004809264 countsByYear W20048092642023 @default.
• W2004809264 crossrefType "journal-article" @default.
• W2004809264 hasAuthorship W2004809264A5018785830 @default.
• W2004809264 hasAuthorship W2004809264A5022177889 @default.
• W2004809264 hasAuthorship W2004809264A5034911775 @default.
• W2004809264 hasAuthorship W2004809264A5046541559 @default.
• W2004809264 hasAuthorship W2004809264A5047698585 @default.
• W2004809264 hasAuthorship W2004809264A5058823472 @default.
• W2004809264 hasBestOaLocation W20048092641 @default.
• W2004809264 hasConcept C126322002 @default.
• W2004809264 hasConcept C134018914 @default.
• W2004809264 hasConcept C167414201 @default.
• W2004809264 hasConcept C2779280383 @default.
• W2004809264 hasConcept C2779922275 @default.
• W2004809264 hasConcept C2909763481 @default.
• W2004809264 hasConcept C555293320 @default.
• W2004809264 hasConcept C71924100 @default.
• W2004809264 hasConceptScore W2004809264C126322002 @default.
• W2004809264 hasConceptScore W2004809264C134018914 @default.
• W2004809264 hasConceptScore W2004809264C167414201 @default.
• W2004809264 hasConceptScore W2004809264C2779280383 @default.
• W2004809264 hasConceptScore W2004809264C2779922275 @default.
• W2004809264 hasConceptScore W2004809264C2909763481 @default.
• W2004809264 hasConceptScore W2004809264C555293320 @default.
• W2004809264 hasConceptScore W2004809264C71924100 @default.
• W2004809264 hasIssue "5" @default.
• W2004809264 hasLocation W20048092641 @default.
• W2004809264 hasLocation W20048092642 @default.
• W2004809264 hasOpenAccess W2004809264 @default.
• W2004809264 hasPrimaryLocation W20048092641 @default.
• W2004809264 hasRelatedWork W1980807338 @default.
• W2004809264 hasRelatedWork W2020274244 @default.

• next